Tesamorelin and visceral fat: the approved use and the trials

Reviewed 15 sourcesPublished by PepVault

Tesamorelin cut deep belly fat about 15% more than placebo in two phase 3 HIV trials, with no weight loss. The approved use, how it works, what came back.

A man slicing a red pepper at a bright kitchen island, a salad bowl of avocado and tomatoes beside him
Last reviewed
Sources
15
Questions
10
Compounds
2

The short answer

Tesamorelin is a lab-made version of the body's growth hormone-releasing hormone, FDA-approved since 2010 for one use: reducing excess abdominal fat in adults with HIV and lipodystrophy. In two phase 3 trials, 26 weeks of daily injections cut visceral fat, the deep fat around the organs, about 15% more than placebo, while body weight stayed flat. Six months after stopping, most of it had returned.

Every number checked at its primary source · · 15 sources · How we research

Evidence: Human trials: two large placebo-controlled phase 3 trials in 806 adults with HIV and their 26-week extensions, plus smaller randomized trials of liver fat in HIV (50 and 61 people), abdominal obesity (60 people) and older adults (152 people).

A man slicing a red pepper at a bright kitchen island, a salad bowl of avocado and tomatoes beside him

What is tesamorelin?

Tesamorelin is the body's full 44-amino-acid growth hormone-releasing hormone (GHRH), the hypothalamus's signal for growth hormone, with one addition: a short six-carbon chain attached to its first link1. Sermorelin, its older relative, keeps only the first 29 links of the same chain. The FDA approved tesamorelin on November 10, 2010, as Egrifta3.

Two forms are sold today, and their labels give different doses. The EGRIFTA SV label's dose is 1.4 mg once daily, from a 2 mg vial mixed fresh each day; the EGRIFTA WR label's is 1.28 mg once daily, from a vial mixed once a week. The labels say the two are not substitutable, and each was approved on matching blood levels with the original 2 mg dose the trials used12.

The molecule itself is brief. After one injection under the skin, its half-life was 8 minutes for EGRIFTA SV and 11 minutes for EGRIFTA WR, measured in healthy adults12. What lasts is the response it sets off.

Try it

How Tesamorelin builds up

An estimate from a half-life of about 0.2 hours, one dose a day for four weeks. The shape of the level, not a measurement.

Try your own scheduleTesamorelin in the library

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault's body check-ins record your waist, a measure the trials also tracked, so its curve sits beside your scans.

Download on the App Store

7 days free on the yearly plan for new subscribers.

How does tesamorelin reduce visceral fat?

It works one step upstream of growth hormone. Tesamorelin binds the GHRH receptor on the pituitary's growth hormone cells, so the pituitary releases more of its own growth hormone in its usual pulses, and the liver answers with more IGF-1, a growth factor that carries part of growth hormone's effect1. Growth hormone breaks down stored fat, and the deep fat inside the abdomen responded most18.

In the two phase 3 trials, IGF-1 rose by an average of 107 and 108 ng/mL over 26 weeks, while it fell 15 ng/mL and rose 3 ng/mL on placebo1. Other pituitary hormones (thyroid, adrenal, reproductive and prolactin) did not change in a meaningful way1. Because the drug needs a working pituitary, the label rules it out after pituitary surgery, head radiation or other damage to that axis1.

Outside HIV, a two-week study in 13 healthy men with an average BMI of 27 showed the same pattern: overnight growth hormone pulses grew larger, IGF-1 rose by 181 μg/L, and insulin sensitivity measured by a glucose clamp did not change12.

How much visceral fat did the trials remove?

Visceral fat was measured as an area on a CT slice at the level of the lower spine, in square centimetres. At the start of the phase 3 trials, the average was 176 to 189 cm²1. Every trial in the table gave 2 mg of the original formulation once daily under the skin.

TrialWhoLengthTesamorelinPlacebo
Phase 2, 2005461 adults with HIV and central fat12 weeks−15.7% (2 mg group)−5.4% (difference not significant)
Phase 3 study 1, 20075412 adults with HIV, 86% men26 weeks−15.2%+5.0%
Phase 3 study 2, 20107404 adults with HIV26 weeks−10.9% (−21 cm²)−0.6% (−1 cm²)
Both phase 3 trials pooled8806 adults with HIV26 weeks−24 cm²+2 cm²; net effect −15.4%
Stanley, 2014950 adults with HIV6 months−34 cm²+8 cm²
Makimura, 20121160 adults with abdominal obesity and low growth hormone output12 months−16 cm²+19 cm²
A schematic CT slice through the abdomen at the lower spine: visceral fat inside the muscle wall shaded apart from the subcutaneous fat ring under the skin
Tesamorelin shrank the inner shaded area; the outer ring under the skin did not change significantly.

The label re-analysed the two phase 3 trials with its own model and reports −18% versus +2% for study 1 and −14% versus −2% for study 21. The fat just under the skin of the abdomen did not change significantly in the pooled trials or the obesity trial811.

Trial 1 kept going for a second 26 weeks: people who stayed on tesamorelin held a visceral fat reduction of about 18% from their starting scan at week 526.

Does visceral fat come back after stopping tesamorelin?

Yes, within six months. At week 26 of each phase 3 trial, people who had been on tesamorelin were re-randomized, without knowing which they got, to keep going or switch to placebo. Over the next 26 weeks, visceral fat in the switched groups rose 25 cm² (22%) in study 1 and 24 cm² (16%) in study 2. In the groups that continued, it changed by +3 cm² and −11 cm²1.

IGF-1 told the same story, falling by 137 and 135 ng/mL after the switch to placebo1. The authors of study 2 put it plainly: the improvements "were rapidly lost" in those who switched7. The effect lasts as long as the daily injections do6.

Change in visceral fat from week 26 to week 52 after re-randomization: the groups switched to placebo rose 25 and 24 cm²; the groups that continued changed by +3 and −11 cm²
Look at week 26: the line that switches to placebo climbs back toward where it started, the line that continues stays down.

Does tesamorelin cause weight loss?

No, and the label says so in its first section: it is "not indicated for weight loss management as it has a weight neutral effect"1. Over 26 weeks, average weight changed by −0.4 kg and +0.5 kg in the two trials, no different from placebo1.

What changed was where the weight sat. Trunk fat fell 1.0 kg and 0.8 kg, lean body mass rose 1.3 kg and 1.2 kg, and the waist shrank an average of 3 cm and 2 cm, against 1 cm on placebo1. Fat came off the middle, lean tissue went on, and the scale barely moved.

Paired bars of 26-week changes in the two phase 3 trials: weight −0.4 and +0.5 kg, trunk fat −1.0 and −0.8 kg, lean mass +1.3 and +1.2 kg
The scale stays nearly flat: the fat that came off the trunk is roughly matched by the lean tissue gained.

What did tesamorelin do to liver fat?

Two smaller trials in people with HIV measured liver fat directly. In the 2014 trial of 50 adults with abdominal fat, 6 months of tesamorelin lowered the liver's lipid-to-water ratio by a median of 2.0 points while it rose 0.9 on placebo9. In the 2019 trial of 61 adults with fatty liver disease, 12 months cut the liver fat fraction by 4.1 points more than placebo, a 37% relative drop, and 35% of the tesamorelin group fell below the 5% line the trial used to enrol, against 4% on placebo10. Fasting glucose and HbA1c did not differ between groups at 12 months10.

Does tesamorelin work outside HIV?

Yes, in a 12-month controlled trial recruited for obesity rather than HIV. Makimura and colleagues gave tesamorelin or placebo to 60 adults aged 18 to 55 with a BMI of 30 or more, a waist of at least 102 cm in men or 88 cm in women, a peak growth hormone of 8 ng/mL or less on a stimulation test, and no diabetes1115. Visceral fat fell 16 cm² against a 19 cm² rise on placebo, triglycerides and C-reactive protein (a marker of inflammation) fell, the carotid artery wall thinned slightly, and fasting glucose and HbA1c did not change11.

A second trial looked at the brain rather than the belly. In 152 adults aged 55 to 87, 66 of them with mild cognitive impairment, tesamorelin at 1 mg each night for 20 weeks improved a combined cognition score and executive function, raised IGF-1 by 117% within the normal range, and lowered percent body fat by 7.4% on a DXA scan. Fasting insulin rose 35% in the group with cognitive impairment, still within the normal range14.

These are two trials in selected groups. The label's approval rests on the HIV trials, and the label adds that long-term cardiovascular safety has not been established1.

What does the label ask doctors to monitor?

Three things, because growth hormone raises IGF-1 and can raise blood sugar1:

  1. Before your first dose, you have your blood sugar checked; the trials enrolled only people with fasting glucose under 150 mg/dL who were not on diabetes medicine1.
  2. During treatment, you have IGF-1 measured at intervals. In the trials, 47% of people had IGF-1 above 2 standard deviation scores (above the usual range for their age) at 26 weeks, and the label suggests considering stopping if it stays above 3, especially when the fat response is weak1.
  3. You have blood sugar rechecked periodically. HbA1c reached 6.5% or higher in 5% of people on tesamorelin and 1% on placebo1.
  4. Along the way, you and your prescriber judge the response: the label asks them to weigh continuing in people whose visceral fat has not come down1. In a later analysis of the phase 3 trials, people whose visceral fat fell 8% or more kept steadier fasting glucose and HbA1c over 52 weeks than those whose fat fell less13.

PepVault's body check-ins record your waist, a measure the trials also tracked, so its curve sits beside your scans. Track your weight in PepVault

Its bloodwork log takes IGF-1, fasting glucose and HbA1c, the numbers behind the label's monitoring. Log it in PepVault

The label also rules tesamorelin out in active cancer, since growth hormone is a growth factor, and in pregnancy, where shrinking visceral fat offers no benefit and could harm the baby1.

What are the side effects of tesamorelin?

Most involve the skin and joints. These are the label's rates over the first 26 weeks of both trials1:

EffectTesamorelin (543 people)Placebo (263 people)
Injection site reaction (redness, itch, pain)17%6%
Joint pain13%11%
Pain in an arm or leg6%5%
Muscle aches6%2%
Swelling in the legs or feet6%2%
Tingling5%2%
Numbness4%2%

The label links the joint aches and swelling to fluid retention from the extra growth hormone, and notes they either pass or resolve once treatment stops1. Counting every kind of skin reaction at the site, the label's rate is 25% against 14%, and rotating injection sites across the abdomen reduces them1. If an allergic reaction is suspected (hives, itching, flushing or a rash beyond the injection site), the label's advice is to stop the drug and get prompt medical care1.

What do people who use tesamorelin report?

Commonly reported: a smaller waist and flatter belly while the scale barely moves, redness or itching where the injection went in, and achy joints in the first weeks that ease with time.

These are user reports, not trial results, though they match the trials' pattern of a smaller waist without weight loss1. The sermorelin guide in this series covers how the shorter GHRH copy was dosed in its own studies.

Track it in the app

Sources

  1. EGRIFTA WR (tesamorelin) for injection, prescribing information. Theratechnologies. DailyMed, SPL version 2, published Aug 3, 2026. dailymed.nlm.nih.gov
  2. EGRIFTA SV (tesamorelin) for injection, prescribing information. Theratechnologies. DailyMed, SPL version 9, published Jul 31, 2026. dailymed.nlm.nih.gov
  3. U.S. Food and Drug Administration. Drugs@FDA: Egrifta (tesamorelin), application 022505, original approval November 10, 2010. accessdata.fda.gov
  4. Falutz J et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS. 2005. PubMed 16052083
  5. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007. PubMed 18057338
  6. Falutz J et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008. PubMed 18690162
  7. Falutz J et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010. PubMed 20101189
  8. Falutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010. PubMed 20554713
  9. Stanley TL et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014. PubMed 25038357
  10. Stanley TL et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019. PubMed 31611038
  11. Makimura H et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012. PubMed 23015655
  12. Stanley TL et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011. PubMed 20943777
  13. Stanley TL et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012. PubMed 22495074
  14. Baker LD et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012. PubMed 22869065
  15. ClinicalTrials.gov NCT00675506. Effectiveness of growth hormone releasing hormone in reducing abdominal fat in people who are obese. Massachusetts General Hospital. clinicaltrials.gov

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo